18F-PSMA-1007
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 228
- Registration Number
- NCT06881823
The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients
- First Posted Date
- 2024-12-09
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Affiliated Hospital of Jiangnan University
- Target Recruit Count
- 50
- Registration Number
- NCT06723665
- Locations
- 🇨🇳
Affiated Hospital of Jiangnan University, Wuxi, Jiangsu, China
Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 380
- Registration Number
- NCT06122584
- Locations
- 🇪🇸
Hospital Vithas Valencia 9 de Octubre, Valencia, Spain
🇪🇸Hospital Del Mar, Barcelona, Spain
🇫🇷CHRU de Nancy, Nancy, France
18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- IRCCS San Raffaele
- Target Recruit Count
- 167
- Registration Number
- NCT05815316
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
- Conditions
- Medullary Thyroid CancerThyroid Cancer, MedullaryThyroid Carcinoma, MedullaryMedullary Thyroid Carcinoma
- Interventions
- First Posted Date
- 2022-09-09
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 15
- Registration Number
- NCT05534594
- Locations
- 🇳🇱
University Medical Centre Groningen, Groningen, Netherlands
18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028
- First Posted Date
- 2022-08-29
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 2800
- Registration Number
- NCT05520255
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
A Head-to-head Comparative Study of 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT Imaging in Multiple Myeloma
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-08
- Lead Sponsor
- First Hospital of China Medical University
- Target Recruit Count
- 30
- Registration Number
- NCT05448404
- Locations
- 🇨🇳
The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Diagnostic Performance of 18F-PSMA-1007 PET/CT in Suspected Prostate Cancer Patient
- First Posted Date
- 2022-06-16
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Primo Biotechnology Co., Ltd
- Target Recruit Count
- 230
- Registration Number
- NCT05422105
- Locations
- 🇨🇳
Tungs'Taichung Metro Harbor Hospital, Taichung, Taiwan
🇨🇳Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
- Conditions
- Prostate CancerProstate Cancer Recurrent
- Interventions
- First Posted Date
- 2021-02-08
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- ABX advanced biochemical compounds GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT04742361
- Locations
- 🇺🇸
Excel Diagnostics and Nuclear Oncology Center, Houston, Texas, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇳🇱RUMC, Nijmegen, Netherlands
Positron Emission Tomography / Magnetic Resonance Imaging (PET/MRI) Guided Biopsy in Men With Elevated PSA
- Conditions
- Prostate Cancer
- Interventions
- Drug: [68Ga]PSMA-11
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2021-09-02
- Lead Sponsor
- Irene Burger
- Target Recruit Count
- 52
- Registration Number
- NCT03187990
- Locations
- 🇨ðŸ‡
University Hospital Zurich, Zurich, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.